{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:21:50Z","timestamp":1719361310166},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,25]]},"DOI":"10.7759\/cureus.63151","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T22:32:17Z","timestamp":1719354737000},"source":"Crossref","is-referenced-by-count":0,"title":["Delayed Diagnosis of Cardiac Amyloidosis Masked by Chronic Coronary Artery Disease and Ischemic Cardiomyopathy: A Case Report of an Overlooked and Underdiagnosed Etiology"],"prefix":"10.7759","author":[{"given":"Azeem","family":"Rathore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanshika","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Kadariya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-020-01781-z","article-title":"Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement","volume":"132","author":"Bonderman D","year":"2020","unstructured":"Bonderman D, P\u00f6lzl G, Ablasser K, et al.. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr. 2020, 132:742-61. 10.1007\/s00508-020-01781-z","journal-title":"Wien Klin Wochenschr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.14797\/mdcvj.1061","article-title":"Clinical clues and diagnostic workup of cardiac amyloidosis","volume":"18","author":"Gill SS","year":"2022","unstructured":"Gill SS, Fellin E, Stampke L, Zhao Y, Masri A. Clinical clues and diagnostic workup of cardiac amyloidosis. Methodist Debakey Cardiovasc J. 2022, 18:36-46. 10.14797\/mdcvj.1061","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2020.11.031","article-title":"Cardiac amyloidosis for the primary care provider: a practical review to promote earlier recognition of disease","volume":"134","author":"Zhang KW","year":"2021","unstructured":"Zhang KW, Vallabhaneni S, Alvarez-Cardona JA, Krone RJ, Mitchell JD, Lenihan DJ. Cardiac amyloidosis for the primary care provider: a practical review to promote earlier recognition of disease. Am J Med. 2021, 134:587-95. 10.1016\/j.amjmed.2020.11.031","journal-title":"Am J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum JN","year":"2017","unstructured":"Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med. 2017, 19:733-42. 10.1038\/gim.2016.200","journal-title":"Genet Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810944","article-title":"Molecular approaches and echocardiographic deformation imaging in detecting myocardial fibrosis","volume":"23","author":"Sonaglioni A","year":"2022","unstructured":"Sonaglioni A, Nicolosi GL, Rigamonti E, Lombardo M, La Sala L. Molecular approaches and echocardiographic deformation imaging in detecting myocardial fibrosis. Int J Mol Sci. 2022, 23:10944. 10.3390\/ijms231810944","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2012.04.013","article-title":"The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients","volume":"164","author":"Dungu J","year":"2012","unstructured":"Dungu J, Sattianayagam PT, Whelan CJ, et al.. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J. 2012, 164:72-9. 10.1016\/j.ahj.2012.04.013","journal-title":"Am Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.08.043","article-title":"Noninvasive diagnosis of biopsy-proven cardiac amyloidosis","volume":"43","author":"Rahman JE","year":"2004","unstructured":"Rahman JE, Helou EF, Gelzer-Bell R, et al.. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2004, 43:410-5. 10.1016\/j.jacc.2003.08.043","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo A","year":"2022","unstructured":"Aimo A, Merlo M, Porcari A, et al.. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail. 2022, 24:2342-51. 10.1002\/ejhf.2532","journal-title":"Eur J Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.749523","article-title":"Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination","volume":"8","author":"Porcari A","year":"2021","unstructured":"Porcari A, Bussani R, Merlo M, Varr\u00e0 GG, Pagura L, Rozze D, Sinagra G. Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination. Front Cardiovasc Med. 2021, 8:749523. 10.3389\/fcvm.2021.749523","journal-title":"Front Cardiovasc Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-016-0311-y","article-title":"New and evolving concepts regarding the prognosis and treatment of cardiac amyloidosis","volume":"13","author":"Perlini S","year":"2016","unstructured":"Perlini S, Mussinelli R, Salinaro F. New and evolving concepts regarding the prognosis and treatment of cardiac amyloidosis. Curr Heart Fail Rep. 2016, 13:267-72. 10.1007\/s11897-016-0311-y","journal-title":"Curr Heart Fail Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"Sattianayagam PT","year":"2012","unstructured":"Sattianayagam PT, Hahn AF, Whelan CJ, et al.. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012, 33:1120-7. 10.1093\/eurheartj\/ehr383","journal-title":"Eur Heart J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson MM","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, et al.. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020, 142:e7-22. 10.1161\/CIR.0000000000000792","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000547","article-title":"Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types","volume":"33","author":"Nativi-Nicolau J","year":"2018","unstructured":"Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol. 2018, 33:571-9. 10.1097\/HCO.0000000000000547","journal-title":"Curr Opin Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams D","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O'Riordan WD, et al.. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018, 379:11-21. 10.1056\/NEJMoa1716153","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018, 379:1007-16. 10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/260893-delayed-diagnosis-of-cardiac-amyloidosis-masked-by-chronic-coronary-artery-disease-and-ischemic-cardiomyopathy-a-case-report-of-an-overlooked-and-underdiagnosed-etiology","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T22:32:19Z","timestamp":1719354739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/260893-delayed-diagnosis-of-cardiac-amyloidosis-masked-by-chronic-coronary-artery-disease-and-ischemic-cardiomyopathy-a-case-report-of-an-overlooked-and-underdiagnosed-etiology"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.63151","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}